glp 1 drugs and ulcerative colitis Today's the day. π¬β¨ From GLP-1s real-world outcomes to engineered biotherapeutics designed for the inflamed colon β and new data on durable remission in #UlcerativeColitis care β #CCCongress26 is bringing the GLP-1 based therapies and disease
Description
Insulin supports blood sugar control and signals the slowing down the emptying of your stomach

Parkinson's disease is a chronic and neurodegenerative brain disorder, and inflammatory activity is one of important features of Parkinson's disease

Significant acute reductions in appetite and food intake were initially observed after intravenous (IV) administration of GLP-1 both in healthy individuals and in patients with T2D

Cardiovascular risk reduction Jardiance is FDA-approved to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease, as well as adults with heart failure and reduced ejection fraction

Clin J Am Soc Nephrol 12:700710 Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM et al (2019) Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: systematic review and meta-analysis of cardio

The Europe GLP-1 market is projected to record substantial growth during the forecast period
